Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma

Nature Clinical Practice Oncology

Volumn 5, Issue 1, 2008, Pages 4-5

  Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AUTOANTIBODY; BCG VACCINE; DACARBAZINE; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ADVANCED CANCER; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; DEPRESSION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FLU LIKE SYNDROME; GENE EXPRESSION PROFILING; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MONOTHERAPY; MYALGIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; T LYMPHOCYTE; VITILIGO; ADJUVANT CHEMOTHERAPY; FOLLOW UP; IMMUNOLOGY; META ANALYSIS; MULTICENTER STUDY; NOTE; PATHOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RISK; SKIN TUMOR; STATISTICS; SURVIVAL; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2B; LYMPHATIC METASTASIS; MELANOMA; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 38449086752     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1007     Document Type: Article

References (11)

1. Markovic SN et al (2007) Malignant melanoma in the 21st century, part 2: Staging, prognosis, and treatment. Mayo Clin Proc 82 490-513
2. Bajetta E et al. (1994) Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12: 806-811
3. Bajetta E et al. (2006) Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17: 571-577
4. Kirkwood JM et al. (1996) Interferon-alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17
5. Kirkwood JM et al. (2000) High- and low-dose interferon alpha-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/ C9190. J Clin Oncol 18: 2444-2458
6. Kirkwood JM et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of intergroup trial E1694/s9512/c509801. J Clin Oncol 19: 2370-2380
7. Kirkwood JM et al. (2004) A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10: 1670-1677
8. Lens MB and Dawes M (2002) Interferon alpha therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 20: 1818-1825
9. Wheatley K et al. (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trial. Cancer Treat Rev 29: 241-252
10. Gogas H et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. New Engl J Med 354: 709-718
11. Bajetta E et al. (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4 75-85